Pay in 4 interest-free payments of $5.22 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Evidence Ledger: What Is Actually Proven
When you choose a GLP-1 dessert that is balanced with protein, you are less likely to have blood sugar spikes
Not for human consumption, medical use, diagnostic applications, veterinary use, or any other in-vivo application
Heres the realistic timeline: Phase 3 trials (AMAZE program): - AMAZE 1 (obesity) started February 2026, enrolling ~1,150 participants - Primary completion estimated: June 2029 - Phase 3 in T2D also being planned following the ADA 2026 data US FDA approval (projected): Q4 2030 at the earliest (GlobalData estimate) EU EMA approval (projected): Q1 2031 at the earliest Bulgaria and Eastern Europe: Typically 612 months after EMA approval for market access, depending on national reimbursement negotiations
Different terms have been used to describe the association of obesity and diabetes
US$ 26.78
US$ 28.16
US$ 20.11
US$ 24.27
US$ 20.02
US$ 21.34
US$ 22.25
US$ 24.32
US$ 29.07
US$ 29.53
US$ 24.11
